Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: Global - Biologics Market (Billion US$), 2014-2020
Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products
Figure 3-3: Global - Biologics Market by Segment (%), 2014
Figure 4-1: Global - Biosimilars Market (Billion US$), 2014-2020
Figure 4-2: Global - Biosimilars Market by Key Geographies (%), 2014
Figure 4-3: Global - Biosimilars Market by Key Geographies (%), 2020
Figure 4-4: Global - Biosimilars Market by Key Segment (%), 2014
Figure 4-5: Global - Biosimilars Market by Key Segment (%), 2020
Figure 4-6: Global - Erythropoietin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-7: Global - HGH Biosimilars Market (Million US$), 2014 & 2020
Figure 4-8: Global - G-CSF Biosimilars Market (Million US$), 2014 & 2020
Figure 4-9: Global - mAb Biosimilars Market (Million US$), 2014 & 2020
Figure 4-10: Global - Insulin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-11: Global - Interferon Biosimilars Market (Million US$), 2014 & 2020
Figure 4-12: Europe - Biosimilars Market (Million US$), 2014-2020
Figure 4-13: Europe - Biosimilars Market by Country (%), 2014
Figure 4-14: Asia - Pacific - Biosimilars Market (Billion US$), 2014-2020
Figure 4-15: Others - Biosimilars Market (Billion US$), 2014-2020
Figure 5-1: World's Best Selling Biologics and their Patent Expiry in the US
Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014
Figure 9-2: Hospira - Breakdown of Revenue by Geographic Segment (%), 2014
Figure 9-3: Hospira - Breakdown of Revenue by Industry Segment (%), 2014
Figure 9-4: Sandoz - Global Sales (Billion USD), 2011-2013
Figure 9-5: Sandoz - Breakdown of Revenue by Geographic Segment (%),2013
Figure 9-6: Stada - Breakdown of Revenue by Industry Segment (%), 2014
Figure 9-7: Teva - Breakdown of Revenue by Geographic Segment (%), 2014

List of Tables:

Table 4-1: Global - Patent Expiry Status of EPOs
Table 4-2: Global - Biosimilar EPOs Approved for Marketing
Table 4-3: Global - Biosimilar EPOs in Pipeline
Table 4-4: Global - Biosimilar HGH Approved for Marketing
Table 4-5: Global - Biosimilar HGH in Pipeline
Table 4-6: Global - Biosimilar G-CSF Approved for Marketing
Table 4-7: Global - Biosimilar G-CSF in Pipeline
Table 4-8: Global - Patent Expiry Status of G-CSF
Table 4-9: Global - Biosimilar mAbs Approved for Marketing
Table 4-10: Global - Biosimilar mAbs in Pipeline
Table 4-11: Global - Patent Expiry Status of mAbs
Table 4-12: Global - Biosimilar Insulin Approved for Marketing
Table 4-13: Global - Biosimilar Insulin in Pipeline
Table 4-14: Global - Patent Expiry Status of Insulin
Table 4-15: Global - Biosimilar Interferons Approved for Marketing
Table 4-16: Global - Biosimilar Interferons in Pipeline
Table 4-17: Global - Patent Expiry Status of Interferons
Table 7-1: Global - Major M&A Activity in the Past Year
Table 9-1: Biocad - Biosimilars Approved for Marketing
Table 9-2: Biocad - Biosimilars in Pipeline
Table 9-3: Celltrion - Key Financials (Million KRW), 2011-2013
Table 9-4: Celltrion - Biosimilars Approved for Marketing
Table 9-5: Celltrion - Biosimilars in Pipeline
Table 9-6: Dong-A Pharmaceutical - Key Financials (Billion Won), 2011-2013
Table 9-7: Dong-A Pharmaceutical - Biosimilars in Pipeline
Table 9-8: Hospira - Key Financials (Million Dollars), 2012-2014
Table 9-9: Hospira - Biosimilars Approved for Marketing
Table 9-10: Hospira - Biosimilars in Pipeline
Table 9-11: Intas - Biosimilars Approved for Marketing
Table 9-12: Intas - Biosimilars in Pipeline
Table 9-13: Sandoz - Biosimilars Approved for Marketing
Table 9-14: Sandoz - Biosimilars in Pipeline
Table 9-15: Stada - Key Financials (Million Euros), 2012-2014
Table 9-16: Stada - Biosimilars Approved for Marketing
Table 9-17: Stada - Biosimilars in Pipeline
Table 9-18: Teva - Key Financials (Million Dollars), 2012-2014
Table 9-19: Teva - Biosimilars Approved for Marketing